Remdesivir: Gilead to help India boost production, promises 450,000 vials
Premium
(MINT PRINT)
Share Via
Read Full Story
Gilead Sciences Inc will give India at least 450,000 vials of its COVID-19 drug remdesivir and donate active pharmaceutical ingredients (APIs) to boost production, it said on Monday.
Gilead said all seven Indian companies licensed to produce remdesivir are scaling up their batch sizes as well as adding new manufacturing facilities and local contract manufacturers.
TRENDING STORIESSee All
2 min read
Premium
1 min read
2 min read
Premium
1 min read
. 08:52 AM IST
The companies had an installed capacity of about 3.9 million units per month as of April 11. Gilead said it will donate APIs to safeguard against disruption of generic supply.
Cipla Doubles Remdesivir Production In India For Unprecedented Demand
The COVID-19 pandemic brought the world to its knees with its sheer virulence and adaptive ability. It forced the scientific community to work at an unprecedented pace to develop therapeutic regimens and vaccines to combat it. As researchers turned to existing drugs with the hopes of tackling the SARS-CoV-2 virus, one drug emerged as a viable candidate Remdesivir. Now, the drug manufactured by the US-based pharmaceutical company, Gilead Sciences, is being turned to as a savior.
Reports emerging from across India have stated that there is an acute shortage of Remdesivir, and sky-rocketing prices; highlighting not just the demand for the drug, but also the faith in it as the second wave sweeps the country. Let us take a look at Remdesivir s journey in the fight against COVID-19
La Nación / Brasil aprobó uso de remdesivir y en Paraguay piden que Salud provea el medicamento lanacion.com.py - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lanacion.com.py Daily Mail and Mail on Sunday newspapers.